gene therapi area increas focu custom fast-
evolv given potenti treat rang genet disord gene
therapi aim replac defect gene healthi one research
consid promis treatment option intract inherit
diseas nearli gene therapi develop aim treat
diseas accord report drug-industri trade group
thermo fisher scientif made major invest emerg space
gene therapi strengthen portfolio compani enter
definit agreement acquir brammer promin name gene
cell therapi domain deal valu cash
brammer form merger brammer
biopharmaceut florida biologix start decad earlier
part univers florida brammer viral vector contract
develop manufactur organ
brammer servic enabl biopharma custom develop
gene therapi gene-modifi cell therapi therebi aid deliv
advanc medicin patient brammer track deliv
revenu expect continu exceed project market
growth rate mid-term thermo fisher expect busi
accret adjust earn per share first full year
combin brammer viral vector capabl tmo gmp
product expertis proprietari bioprocess cell cultur
technolog uniqu posit partner custom drive
evolut incred fast-grow market transact perfectli
align mission enabl custom make world healthier
cleaner safer
thermo fisher scientif inc brammer leader viral vector
manufactur gene cell therapi announc march
enter definit agreement thermo
fisher acquir brammer cash
brammer lead viral vector contract develop manufactur
organ enabl biopharma custom deliv breakthrough
medicin patient unleash potenti gene therapi gene-
modifi cell therapi busi nearli employe primari
locat massachusett florida busi own founder
privat equiti firm ampersand capit partner
brammer track deliv revenu expect
continu exceed project market growth rate mid-
term thermo fisher expect busi accret adjust earn
per share first full year ownership
transact expect complet end second
quarter subject customari close condit includ
upon complet acquisit brammer becom part
thermo fisher pharma servic busi within laboratori product
servic segment lp segment revenu increas
adjust oper margin
thermo fisher report result pharma servic busi
within laboratori product servic pharma servic consist sole
legaci busi patheon thermo fisher acquir
deal expand buyer market
underway expans announc last year center
excel coe biolog commerci manufactur site st loui
march thermo fisher disclos plan expans capac
steril liquid lyophil product develop commerci
manufactur site monza ferentino itali greenvil nc
brammer excit addit pharma servic busi
strengthen thermo fisher leadership serv pharma
biotech custom thermo fisher stock around far
give market capit
brammer llc develop manufactur cell gene therapi
pharmaceut biotechnolog industri offer pre-clin process
analyt develop process optim process scale-up process
analyt qualif clinic commerci suppli drug substanc
formul drug product
brammer formerli known brammer pharmaceut llc
chang name brammer llc april brammer llc
incorpor base cambridg massachusett
brammer best-in-class viral vector contract develop
manufactur organ gene therapi innov brammer
execut project suppli first-in-human gene therapi clinic trial
phase commerci cgmp viral vector
manufactur site cambridg
warehous distribut center somervil
earli clinic campu alachua fl consist three
build process develop analyt develop facil adjac
cgmp phase i/ii clinic manufactur oper third warehous
offic build
brammer say cgmp facil design accommod spatial
segreg viral vector process dedic product suit support
earli phase clinic trial brammer expect oper
addit lexington facil includ commerci
readi grade clean room viral vector manufactur
maintain buy rate upgrad tp
tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti expect
sales/shar
respect forward-look p/
estim base follow factor strong
growth asia-pacif emerg market strong growth
across busi new product launch
year acquisit divestitur made
thermo fisher deliv strong perform year
due growth asia-pacif emerg market
integr patheon total revenu increas
estim
adjust ep increas
estim
thermo fisher sign agreement sell anatom
patholog busi phc hold corpor
cash anatom patholog busi provid
microscop slide instrument consum
busi gener annual revenu part
thermo fisher specialti diagnost segment therefor
expect growth revenu growth
revenu
mn except ep crispidea namethermo fisher scientif tickertmostock ratingbuyunchangedindustri viewoverweightpositivepric apr week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth thermo fisher scientific| march
thermo fisher scientif inc brammer leader
viral vector manufactur gene cell therapi
announc enter definit
agreement thermo fisher acquir brammer
cash
thermo fisher invest launch
rang new product strengthen lead offer
includ thermo scientif vanquish duo uhplc
sequenc system phadia allergi
autoimmun instrument europ
orbitrap tribrid exact uhmr mass
spectromet system launch asm
see strong adopt custom
current price-to-earnings averag price-to-earnings
due increas stock price quarter
price-to-earnings trail avg-
past consid strong growth
expect forward price-to-earnings multipl
recommend buy rate thermo fisher scientif
base perform expect growth
growth revenu base tmo
expect acquisit divestitur made
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date last split factor new per last split date jun inform thermo fisher scientific| ch
non- reconcili refer pg
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli thermo fisher scientific| march
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item thermo fisher scientific| march
provid oper activ increas account receiv
inventori use cash respect support growth sale
invest activ use cash acquisit use cash invest
activ also includ purchas properti plant equip januari
compani enter agreement sell anatom patholog busi
corpor
financ activ use cash repay senior note use cash
new long-term borrow provid cash net decreas commerci paper oblig
use cash tmo financ activ also includ repurchas tmo
common stock payment cash dividend
depreciation- defer incom oper increas decreas increas decreas current decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end thermo fisher scientific| march
deliv strong quarterli result due increas scale asia-pacif
total revenu grew compar
organ revenu growth acquisit increas revenu
currenc translat decreas revenu
revenu increas compar
cog sale compar
sg expens increas compar
sg expens total revenu
compar total revenu
 expens increas compar
 expens total revenu
compar total revenu restructur cost
compar
total revenu grew
compar
compar
due decreas
oper incom increas compar
oper margin compar
interest incom increas compar
interest expens compar
effect tax rate compar
net incom increas compar
due decreas incom tax
gaap ep increas compar
adjust ep increas compar
total revenu increas compar
organ revenu growth acquisit increas
revenu currenc translat increas revenu year
cost revenu increas compar
cog revenu compar
sg expens increas compar
sg expens revenu compar
 expens increas compar
 expens revenu compar
restructur cost compar
amort acquisition-rel intang asset increas
compar
compar
compar
oper incom increas compar
adjust oper incom increas
compar oper margin
compar increas oper incom due profit
higher sale effect acquisit product improv
net inflationari cost increas
interest incom increas compar
interest expens compar
effect tax rate compar
net incom increas compar
net margin compar adjust
net incom increas compar
ep increas compar
adjust ep increas compar
revenu geograph region
total revenu north america europ grew high-singl digit
asia-pacif grew low teen includ anoth quarter strong
growth china rest world grew mid-singl digit
north america grew mid-singl digit europ rest
world grew high single-digit asia-pacif grew mid-teen
revenu end-market
pharma deliv low teen growth quarter
continu see strength busi serv end market
lead posit pharma led mid teen growth year
diagnost healthcar good growth transplant
diagnost amino diagnost clinic diagnost busi
end market grew mid-singl digit quarter
industri appli deliv growth quarter led
strong perform across analyt instrument busi
grew high single-digit
academ govern saw continu strong demand across
life scienc solut analyt instrument busi
research channel also perform well grew mid-singl digit
quarter
compar
industri appli
growth
quarter led strong
perform across
provid analyt instrument equip reagent consum
softwar servic research manufactur analysi discoveri
diagnost oper four segment life scienc solut analyt
instrument specialti diagnost laboratori product servic
total revenu ai segment increas
compar total revenu increas
compar
sale increas due higher revenu exist busi due
acquisit due favor effect currenc translat
increas revenu exist busi due increas demand
segment busi
oper incom margin compar
oper incom increas
compar increas result profit higher
sale product improv net inflationari cost increas
total revenu
ai segment increas
compar
margin
compar
laboratori product servic segment lp
total revenu lp segment increas
compar total revenu increas
compar
total revenu
compar
sale increas due acquisit due higher
revenu exist busi due favor effect
increas revenu exist busi due increas demand
segment princip busi particular strength
research safeti market channel busi clinic trial busi
total revenu lss
segment increas
compar
oper incom margin compar
decreas due unfavor sale mix strateg growth
invest off-set part profit higher sale oper incom
increas compar
total revenu lss segment increas
compar total revenu increas
compar
sale increas due higher revenu exist busi due
favor effect currenc translat due acquisit
increas revenu exist busi due increas demand
segment busi particular strength sale
bioscienc product bioprocess product product
oper margin compar
oper incom increas compar
increas oper margin result profit
higher sale product improv net inflationari cost increas
total revenu special diagnost segment increas
compar total revenu
increas compar
sale increas due higher revenu exist busi due
favor effect currenc translat due
acquisit increas revenu exist busi due broad
base higher demand segment busi particular
strength sale product sold segment healthcar market
oper margin compar
decreas result strateg growth invest unfavor sale
mix oper incom increas compar
total revenu
segment increas
compar
sale increas due
higher revenu
due
favor effect
currenc translat
due
expect revenu
adjust ep estim
net capit expenditur expect
gene therapi area increas focu custom fast-
evolv given potenti treat rang genet disord gene
therapi aim replac defect gene healthi one research
consid promis treatment option intract inherit
diseas nearli gene therapi develop aim treat
diseas accord report drug-industri trade group
thermo fisher scientif made major invest emerg space
gene therapi strengthen portfolio compani enter
definit agreement acquir brammer promin name gene
cell therapi domain deal valu cash
brammer form merger brammer
biopharmaceut florida biologix start decad earlier
part univers florida brammer viral vector contract
develop manufactur organ
brammer servic enabl biopharma custom develop
gene therapi gene-modifi cell therapi therebi aid deliv
advanc medicin patient brammer track deliv
revenu expect continu exceed project market
growth rate mid-term thermo fisher expect busi
accret adjust earn per share first full year
combin brammer viral vector capabl tmo gmp
product expertis proprietari bioprocess cell cultur
technolog uniqu posit partner custom drive
evolut incred fast-grow market transact perfectli
align mission enabl custom make world healthier
cleaner safer
thermo fisher scientif inc brammer leader viral vector
manufactur gene cell therapi announc march
enter definit agreement thermo
fisher acquir brammer cash
brammer lead viral vector contract develop manufactur
organ enabl biopharma custom deliv breakthrough
medicin patient unleash potenti gene therapi gene-
modifi cell therapi busi nearli employe primari
locat massachusett florida busi own founder
privat equiti firm ampersand capit partner
brammer track deliv revenu expect
continu exceed project market growth rate mid-
term thermo fisher expect busi accret adjust earn
per share first full year ownership
transact expect complet end second
quarter subject customari close condit includ
upon complet acquisit brammer becom part
thermo fisher pharma servic busi within laboratori product
servic segment lp segment revenu increas
adjust oper margin
thermo fisher report result pharma servic busi
within laboratori product servic pharma servic consist sole
legaci busi patheon thermo fisher acquir
deal expand buyer market
underway expans announc last year center
excel coe biolog commerci manufactur site st loui
march thermo fisher disclos plan expans capac
steril liquid lyophil product develop commerci
manufactur site monza ferentino itali greenvil nc
brammer excit addit pharma servic busi
strengthen thermo fisher leadership serv pharma
biotech custom thermo fisher stock around far
give market capit
thermo fisher built excel growth momentum asia-pacif
emerg market due strong perform china total revenu
increas adjust ep increas
invest launch rang new product
strengthen lead offer includ thermo scientif vanquish duo
genestudio seri next-gener sequenc system phadia
allergi autoimmun instrument europ recent open first
bioprocess design center support develop biolog
analyt instrument busi continu strengthen thermo scientif
brand build lead platform across chromatographi mass
spectrometri electron microscopi
life scienc solut busi continu strengthen ion torrent
line next-gen sequenc genestudio seri benchtop
instrument launch invitrogen evo digit microscop
cell imag highlight good start
specialti diagnost busi launch two import instrument
brahm kryptor gold autom immunoassay system
phadia benchtop analyz help doctor diagnos allergi autoimmun
continu success execut capit deploy strategi
creat signific sharehold valu reduc debt close
bolt-on acquisit return capit stock
buyback dividend
continu
success execut
strategi
reduc debt
close bolt-
acquisit
return capit
stock
buyback
non- reconcili
non- reconcili
non- reconcili
gross margin declin compar due increas cog
revenu growth compar
ep growth compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth thermo fisher scientific| march
mrqgross mrqcog mrqoper mrqnet mrqr mrqsg sale thermo fisher scientific| march
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale thermo fisher scientific| march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item thermo fisher scientific| march
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas investment- sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free thermo fisher scientific| march
current price-to-earnings averag price-to-earnings due increas stock price
quarter price-to-earnings trail past
consid strong growth expect forward price-to-earnings multipl
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc massachusett servic capit research global price row associ capit world wellington manag compani fmr america thermo fisher scientific| march
developmentsthermo fisher scientif acquir brammer leader viral vector manufacturingmarch fisher scientif inc brammer leader viral vector manufactur gene cell therapi announc enter definit agreement whichthermo fisherwil acquir brammer cash brammer track deliv revenu expect continu exceed project market growth rate mid-term thermo fisher expect busi accret adjust earn per share first full year ownership thermo fisher scientif launch new softwar streamlin qualiti test craft brewingmarch beer brewer access econom solut design streamlin qualiti assur test achiev batch-to-batch consist newthermo scientif beercraftsoftwar packag thermo scientif spectrophotomet togeth thermo scientif beercraft softwar uv-vi spectrophotomet afford easy-to-us system provid american societi brew chemist-qu test method beer attribut includ color bitter protein sugar carbohydr polyphenol level thermo fisher scientif launch new dosimetri monitor servicefebruari new dosimetri monitor servic thermo fisher scientif enabl medic imag facil dental offic veterinari clinic nuclear power plant laboratori facil radiat safeti requir streamlin manag safeti program thermo scientif dosimetri servic design enabl facil oper monitor track individu employe accumul radiat dose precis accuraci thermo fisher scientif sign agreement sell anatom patholog businessjanuari fisher scientif inc announc sign definit agreement sell anatom patholog busi phc hold corpor global innov healthcar solut cash anatom patholog busi provid microscop slide instrument consum employe locat europ china busi gener approxim annual revenu part thermo fisher specialti diagnost segment thermo fisher scientific| march
compar
gross margin ttm
compar
industri averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit thermo fisher scientific| march
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
higher
annual usdgrowth high day day day estim avgfive-year growth forecast comparisontmoindustri avg avgprice/earn yield thermo fisher scientific| march
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last daysn/an/an/an/aup last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr thermo fisher scientific| march
stock price shown upward trend quarter surg march
stock given return period averag volum share trade
share
stock price volatil dip decemb later surg
rang stock gave return year
stock price show huge growth past surg march
stock given return past gave strong perform y/i
thermo fisher scientif deliv strong perform due strong growth across segment
end-market also launch new product strong growth china maintain buy
rate stock tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
